Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned an average rating of “Hold” from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $9.33.
Several equities analysts have recently issued reports on the company. Royal Bank of Canada cut Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their target price for the company from $15.00 to $4.00 in a research note on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. Leerink Partners reissued a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright cut Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $17.00 to $4.00 in a research report on Friday, September 13th.
Check Out Our Latest Analysis on FULC
Institutional Inflows and Outflows
Fulcrum Therapeutics Stock Down 5.3 %
Shares of NASDAQ FULC opened at $3.57 on Tuesday. The company has a market cap of $221.89 million, a price-to-earnings ratio of -2.23 and a beta of 2.23. The firm’s fifty day moving average is $7.46 and its 200 day moving average is $7.66. Fulcrum Therapeutics has a 52 week low of $2.87 and a 52 week high of $13.70.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%. The company had revenue of $80.00 million during the quarter, compared to analyst estimates of $80.00 million. During the same period in the prior year, the business posted ($0.38) earnings per share. Equities research analysts anticipate that Fulcrum Therapeutics will post -0.28 earnings per share for the current year.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Featured Articles
- Five stocks we like better than Fulcrum Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- The Significance of Brokerage Rankings in Stock Selection
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How to Calculate Stock Profit
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.